By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Jounce Therapeutics 

1030 Massachusetts Avenue

Cambridge  Massachusetts  02138  U.S.A.
Phone: 857-259-3840 Fax: 617-812-5345


Jounce Therapeutics is focused on the discovery and development of novel cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.

This transformational approach has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life.

Jounce is building upon the unparalleled expertise of its renowned scientific founders – world leaders in the fields of immunology, cancer biology and clinical and translational medicine in cancer – and its increasing understanding of how cancer cells communicate and interact with the immune system to position the company at the forefront of cancer immunotherapy drug discovery and development.

Based in Cambridge, Mass., Jounce is a private company launched in 2013 with $47 million in Series A venture capital financing by Third Rock Ventures.

Key Statistics

Ownership: Public

Web Site: Jounce
Employees: n/a
Symbol: JNCE


Company News
Jounce (JNCE) Names Ex-Ariad (ARIA)'s Top Dealmaker as Its New CBO 8/15/2017 7:40:27 AM
Jounce (JNCE) Reports Second Quarter 2017 Financial Results 8/9/2017 1:07:42 PM
Jounce (JNCE) To Announce Second Quarter 2017 Financial Results And Host Conference Call On Wednesday, August 9, 2017 8/2/2017 1:14:19 PM
OncoSec Medical Announces Technology Access Program Agreement With Jounce (JNCE) 6/12/2017 8:13:27 AM
Jounce (JNCE) Presents Phase I Data From ICONIC Study Of JTX-2011 In Patients With Advanced Solid Tumors At 2017 ASCO Annual Meeting 6/5/2017 11:49:55 AM
Jounce (JNCE)'s Number One Employee Rejoins Constellation Pharma as New CEO 5/25/2017 6:32:08 AM
Jounce (JNCE) To Present Phase I Data From JTX-2011 ICONIC Trial At 2017 ASCO Annual Meeting 5/18/2017 12:24:46 PM
Jounce (JNCE) Reports First Quarter 2017 Financial Results 5/9/2017 10:10:25 AM
Jounce (JNCE) Initiates Phase II Portion Of ICONIC Study Of JTX-2011 In Patients With Advanced Solid Tumors 4/21/2017 10:57:49 AM
Cambridge Biotech Jounce (JNCE) Bounces on the IPO Scene, Raises $102 Million 1/27/2017 5:29:14 AM